Entecavir has been cut 55%!

Source: Chongqing Morning Post 2016-12-12 entecavir attracted attention again in Chongqing pharmaceutical market with a maximum decrease of 55% Two weeks ago, Chongqing Morning Post said that "the same drug sold in Chongqing for 140 yuan, and sold in Fujian for 46 yuan?"? 》For the title, the different prices of the same antiviral drug entecavir for hepatitis B were reported The leading role in the report was that 0.5mg × 7 capsules of entecavir were packed in boxes, and the price of each box in the hospital was 140 yuan Now, the same box of 0.5mg × 7 capsules of entecavir in the official information of the Second Affiliated Hospital of heavy medicine shows that the current price is 63.08 yuan / box, a decrease of 55% First line hepatitis B drug price cut 55% entecavir price news first in the hepatitis B patients in the group caused a shock On December 6, a hepatitis B patient in Chongqing said that he had bought entecavir capsules at a reduced price in the Second Affiliated Hospital of Chongqing Medical University, and the 0.5mg × 7 capsules in boxes reduced to 63.08 yuan per box Professor Yu Zujiang, chief physician of infectious diseases department of the First Affiliated Hospital of Zhengzhou University, once wrote that entecavir is the best antiviral drug (with the lowest risk of drug resistance) among the current hepatitis B oral drugs, and its virus inhibition ability is nearly 10 times higher than that of adefovir Therefore, it is suitable for all people with different viral load, and most of the patients can reach 6 Within months, the virus quickly turned negative, so the ability to control the disease was the strongest For the drug resistance problem in the first-line drugs, entecavir is the lowest drug resistance among all antiviral drugs, and it is the least prone to virus mutation The risk of drug resistance in six years is only 1.2%, which is very encouraging But correspondingly, entecavir is also a relatively high price drug at present Although in recent years, due to the increase of generic pharmaceutical enterprises and the decrease of the price of entering multiple reimbursement catalogue, there is still a great economic pressure for patients who need to take medicine for a long time In an interview with Chongqing Morning Post, a patient said that he had taken 0.5mg × 7 capsule of entecavir in a box of a brand before, which was prescribed from the hospital, 140 yuan per box, 1 capsule per day, 4 boxes per month, and 6720 yuan per year; after the price reduction, drugs with the same name, measurement and manufacturer dropped to 63.08 yuan, 3692 yuan per year could be saved Yuan Not only that, it is reported that different dosage forms, including entecavir (Runzhong) dispersible tablets, have declined in varying degrees under the price adjustment of Chongqing drug exchange After the adjustment, the price of the drug is lower than the average bid price of each province, close to the lowest price in Fujian Province In 2010, Chongqing was the first to set up a drug exchange in China, which became the first public platform for the whole process electronic trade of the third-party medicine The purpose of its establishment is to establish a new mechanism for the circulation of medicine, reduce the cost of drug trade, promote the establishment of a scientific and reasonable mechanism for the formation of drug prices, and promote the rational return of drug prices Two thousand and fourteen In, the Chongqing drug exchange supervision and Administration Committee printed and distributed the notice of "dynamic adjustment method of drug market entry price of Chongqing drug exchange (Revised)" In one of the special adjustment provisions, if the transaction price of listed products is falsely higher than the actual market transaction price, the relevant functional departments of the exchange supervision and Administration Committee shall investigate and verify and report to the exchange supervision and Administration Committee for study and handling The exchange shall adjust the entry price in accordance with the decision and relevant rules According to the news report, the price of entecavir capsule from November 140 yuan per box to now 63.08 yuan is due to the intervention of Chongqing drug exchange However, outside Chongqing, the actual sales price of entecavir in hospitals across the country is still very different On May 20, the national health and Family Planning Commission announced that the three drugs of lung cancer and hepatitis B were included in the first batch of national drug price negotiation list The three drugs of gefitinib of AstraZeneca in the United Kingdom for the treatment of advanced non-small cell lung cancer, exetinib of Beida in Zhejiang Province, and Werder (GSK) for the treatment of chronic hepatitis B decreased by 55%, 54% and 67%, respectively Among them, the only hepatitis B drug, Werder, led the decline by 67%, and made the price of China the lowest in the world after the price reduction, which attracted a lot of praise in the market and hepatitis B patients This system is also considered to be an innovation between the adjustment of public demand for drugs and the actual ability to pay At that time, it was pointed out that for China, which has become the world's largest liver disease country, it is very necessary to integrate first-line drugs such as entecavir into the national or local drug price negotiation system.